EGFR and non-small cell lung carcinoma: Subsequently, the FLAURA study demonstrated that osimertinib was more efficient than first‐generation EGFR‐TKIs and was rapidly approved as a first‐line treatment of advanced EGFR‐mutant NSCLC, regardless of T790M mutation status.3